VIVES is a multi-sector fund that invests in projects with a positive societal impact
Keemotion has developed a motion detection technology. Their proprietary software offers a complete solution for coaches, leagues and broadcasters. Thanks to Keemotion, your organization produces...
ViroVet is a pioneering company developing innovative technologies to combat viral diseases in livestock. They focus on antiviral drugs for complex respiratory illnesses and novel vaccines to protect...
Founded at the end of the nineties, NeuroTECH was co-founded by Mr. Troosters and three members of UCLouvain (Prof. C. Trullemans, Prof. Cl. Veraart and Dr. J. Delbeke).
During the first years and in...
Denis Périquet, CEO Tessares:
"VIVES supports real innovation projects, while understanding that those projects need time to grow from the academic research phase to a commercial success. Team...
Vincent Mouret, Chairman of the Board of Cissoid:
"As Chairman of the board of Cissoid, I’ve been working closely to VIVES for the last 10 years. I have really appreciated VIVES involvement and...
David Frenay, CEO Emolytics:
"Emolytics is a spin-off of the UCLouvain, founded in 2014 and acquired by Profacts in 2018. Emolytics has been supported by VIVES II Fund since its inception, as VIVES...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is
NVD003 is a bone grafting material developed to surgically treat patients with Congenital Pseudarthrosis of the Tibia, a rare and difficult-to-treat pediatric disease
Four young patients were treated